ClinicalTrials.gg
CompletedNCT05115669Updated Feb 21, 2023

Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts

An interventional study of Wortie freeze plus in Common Wart and Plantar Wart, sponsored by Karo Pharma AB. Completed at 1 site in Poland. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Karo Pharma AB · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

This is a Post-Market clinical Follow-up investigation to evaluate the safety and performed of the medical device Wortie Freeze Plus in the treatment of common and plantar warts.

02

Conditions studied

  • Common Wart
  • Plantar Wart

Browse trials for

03

In context

Warts

172 studies on the registry are indexed under Warts; 36 are open to participants now.

This study's enrollment of 50 is below the median of 70 across 156 interventional studies indexed under Warts.

Browse Warts studies →

Lead sponsor

Karo Pharma AB is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects.
  2. Sex: male or female.
  3. Age: 12 years old and above.
  4. Subjects presenting at least 1 common wart (present since less than 6 months) on the fingers or back of the hands, and/or plantar wart (40-60% subjects with common wart) of a size less than 1 cm.
  5. Subject, including minors having more than 12 years old, having given freely and expressly his/her .
  6. Minor whose legally designated representative have given their free and express informed consent.
  7. Subject affiliated to a health social security system.
  8. Female of should use a regimen recognized as effective since at least 12 weeks before screening visit, during all the study and at least 1 month after the study end

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing woman or planning a pregnancy during the study.
  2. Subject who had been deprived of their freedom by administrative or legal decision.
  3. Major subject who is under guardianship or who is not able to express his consent.
  4. Subject in a social or sanitary establishment.
  5. Subject suspected to be non-compliant according to the Investigator's judgment
  6. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.
  7. Subject with a cutaneous disease other than common warts, on the studied zone.
  8. Subject with a known allergy to one of the components of the device or conductive gel.
  9. Subject who has diabetes.
  10. Subject having problems with blood circulation or having a blood clotting condition.
  11. Subject with immune deficiency or disease.
  12. Subject presenting more than 10 warts on the body
  13. Subject presenting bleeding warts.
  14. Subject presenting birthmarks, moles, warts with hairs growing from them, or any other spots on the treated and surrounding area.
  15. Subject having a sensitive, inflamed, infected, irritated, red, damaged, cut, grazed, diseased or itchy skin on or around the treated zone.
  16. Subject presenting genital warts, flat warts, filiform warts, periungual warts or warts with hairs growing from them.
  17. Subject presenting 2 or more warts adjacent to each other
  18. Subject undergoing a topical treatment on the test area or a systemic treatment: anti-inflammatory medication and/or antihistamines during the 2 weeks prior to screening and during the study; or during the 2 weeks prior to screening and during the study; or retinoids and/or immunosuppressors during the 3 months prior to screening and during the study; or any medication stabilized for less than a month
  19. Subject who received a treatment of any type on the selected wart during the previous 6 months.
  20. Subject having started or changed her oral or any other hormonal treatment during the three previous months
  21. Intensive exposure to sunlight or UV-rays on the studied zone within the previous month and/or foreseen during the study.
  22. Subject planning to change her/his life habits during the study.
  23. Subject with excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Wortie freeze plus

    Cryogenic medical device (dimethylether-based product) + conductive gel + protective foam plasters. Up to 3 applications one every 14 days

    Device: Wortie freeze plus

Interventions

  • DeviceWortie freeze plus

    treatment of common and plantar warts

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with cured wart after maximun 3 treatments evaluate by the investigator

    Time frame: Day 42

Secondary outcomes

  1. Percentage of subjects with cured wart after 1, 2 and 3 treatments evaluated by the investigator common and plantar warts after 1, 2 and 3 treatments as assessed by the investigator

    Time frame: Day 14, Day 28, Day 42

  2. Percentage of subjects with improved aspect of the wart after 1, 2 and 3 treatments evaluated by the investigator

    Time frame: Day 14, Day 28, Day 42

  3. Mean frostbite area diameter after each treatment

    Time frame: Day 0, Day 14, Day 28

  4. Percentage of subjects satisfied with the treatment by answering a questionnaire at the study end

    Time frame: Day 14, Day 28, Day 42

  5. Illustration of the skin aspect by pictures before and after each treatment

    Time frame: Day 0, Day 14, Day 28

  6. Mean subject' pain during treatment evaluated using a using a 11-item (0-10) Numerical Rating Scale

    0= no pain; 10= worst possible pain

    Time frame: Day 0, Day 14, Day 28

  7. Subject tolerability evaluated at the study end by the investigator using a 4-item (0-3) Numerical scale

    0=bad tolerance; 1= moderate tolerance; 2= good tolerance; 3 = very good tolerance

    Time frame: Day 14,Day 28, Day 42

  8. Collection of adverse events throughout the study

    Time frame: Day 0, Day 14, Day 28, Day 42

07

Study locations

1 site
  • Eurofins Dermascan Poland
    Gdańsk, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in May 2022, 6 months.

Of 29 interventional studies with no phase under Warts, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Nov 10, 2021
StartActual
Oct 12, 2021
Primary completionActual
May 1, 2022
CompletionActual
May 1, 2022
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05115669
Lead sponsor
Karo Pharma AB
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Oct 12, 2021
Primary completion
May 1, 2022
Completion
May 1, 2022
Last update
Feb 21, 2023

Study contacts

Agnieszka Cegielska, MD
principal investigator · Dermascan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion